Tag: targeted therapy
Remegen’s Disitamab Vedotin Attracts China’s largest-ever out-license Agreement at US $...
Earlier this month, Remegen Biosciences, a Shandong-based biotech company operating since 2008, scored the largest ever out-license deal for a Chinese biotech company when...
New Combination with HuMax-AXL-ADC Leads to Personalized Cancer Treatment 2.0
Tumors often comprise groups of cancer cells that show differential drug sensitivities. This is one of the reasons that initially effective treatments usually do...
Europe-wide Training Network Focuses on Targeted Anticancer Drug Development
Currently used anticancer drugs are highly cytotoxic and therapies are often associated with multiple, severe adverse events. For decades drug developers have been working...
